acs 2
 
bar

program

slides

  test

syllabus
bar
 
 

Acute Pressure Syndromes

From Threat to Therapy
National Congress
Seatte, WA

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This symposium is designed for emergency medicine specialists, emergency medicine fellows, emergency medicine nurses, nurse practitioners (NPs) with EM concentration, physician assistants (PAs) with emergency medicine focus, prehospital care providers, cardiologists and cardiovascular specialists, critical care physicians and intensivists

Registration:

Enrollment for this webcast is complimentary, and clinicians are invited to attend this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

rocheSupported by an independent educational grant from The Medicines Company, Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

James Ferguson III, MD, FACC
Grant/Research Support: Eisai, The Medicines Company, Viatron/Medtronic
Consultant: BMS, Eisai, Prism, Sanofi-Aventis, Schering Plough, Takeda, The Medicines Co., Therox
Speaker’s Bureau: BMS, Sanofi-Aventis, Schering Plough

Frank Peacock, MD, FACEP
Grant/Research Support: Abbott, Accumetrics, Biosite, CHF Solutions, Inovise, Inverness, Scios,
The Medicines Co., Vital Sensors
Consultant: Abbott, Beckman-Coulter, Biosite, Inovise, Inverness, Ortho Clinical Diagnostics, PDL, Scios, The Medicines Co., Vital Sensors
Speaker’s Bureau: Abbott, Scios, PDL, Biosite
Major Shareholder: Vital Sensors

Charles V. Pollack, MD, FACEP
Grant/Research Support: GlaxoSmithKline
Consultant: The Medicines Co., Schering-Plough, Sanofi-Aventis, BMS, Genentech
Speaker’s Bureau: Schering-Plough, Sanofi-Aventis, BMS, Genentech

Program Faculty:

James Ferguson III, MD, FACC
Associate Director, Cardiology Research
Texas Heart Institute at St. Luke’s
Episcopal Hospital
Associate Professor
Baylor College of Medicine
Clinical Assistant Professor
University of Texas Health Science Center
at Houston
Houston, Texas

Frank Peacock, MD, FACEP
Professor of Emergency Medicine
Department of Emergency Medicine
Cleveland Clinic Hospitals and Clinics
Cleveland, Ohio

Charles V. Pollack Jr, MA, MD, FACEP, FAAEM
Chairman, Department of Emergency Medicine
Pennsylvania Hospital
Professor of Emergency Medicine
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Educational Objectives:

Participants will:

  • Learn to identify underlying chronic and acute precipitants of acute elevations in systemic blood pressure and how these syndromes presents across multiple disease states and patient populations.
  • Learn to assess and implement optimal phar macologic interventions for patients presenting with manifestations of acute pressure syn dromes, including elevated systolic or diastolic blood pressure, end organ dysfunction, and other cardiovascular, renovascular, and/or neurovascular derangements.
  • Learn to characterize, identify, and evaluate myriad, acute disease states producing serious and/or life-threatening elevations in systemic blood pressure, among them: hypertensive urgency, hypertensive crisis, ischemic stroke,
    drug-induced acute pressure syndromes, subarachnoid hemorrhage, intracerebral hemorrhage, pulmonary edema, and related conditions.
  • Learn to understand the specific advantages and potential disadvantages of currently available intravenously administered pharmacologic agents used to reduce acute, serious, and/or life-threatening elevations in systemic blood pressure.
  • Learn to identify the ideal properties of intravenous agents used to provide emergency- and critical care-based lowering of potentially serious and/or life-threatening elevations in systemic blood pressure.
  • Learn to discuss and assess the impact that new trials and novel agents are likely to have on future management of patients with acute pressure syndromes.
  • Learn to apply national guidelines and expert, consensus-based recommendations in order to optimize emergency-based therapy of patients with serious, systemic elevations in blood pressure.

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations

bar

program

slides

  test

syllabus
bar

YES, I have read the CME information statement

Copyright (c) 2007 All rights reserved


 
6

 

 

 

 

Key Program Topics Include:
b-blockers
ACE Inhibitors
Acute coronary syndrome
Acute heart failure
Acute Myocardial Infarction
Acute Pressure Syndromes
Acute pulmonary edema
Acute renal failure
Anticoagulants
Antiplatelets
Aortic coarctation
Arrhythmia
ASA
aspirin
BP
Brain
Calcium Channel Blockers
Cardiopulmonary
Charles V. Pollack
Chest pain
Clevidipine
Clonidine
clopidogrel
CNS
Cushing’s syndrome










CVA
diabetes
Diastolic
Diazoxide
Dihydropyridine
Dissecting aorta
Diuretics
Dyspnea
Eclampsia
Elevated ICP
Emergency
End-Organ Damage
Epistaxis
Esmolol
Essential hypertension
Exudates
Fenoldopam
Ferguson
Frank Peacock
GP IIb/IIIa antagonist
Headache
Heart
Hemodynamics
Myocardial Ischemia
Heparin
Hydralazine
Hyperparathyroidism

Hypertension
Hypertensive
hypertensive crisis
Hypertensive Emergencies
Hypertensive encephalopathy
Hyperthyroidism
Isolated Systolic Hypertension
Kidneys
Labetolol
LMWH
Low molecular weight heparin
Lytic
MAP
MgSO4
Neurologic deficits
Neurologic Insult
Neurovascular Insults
Nicardipine
Nitrendipine
Nitroglycerin
Nitroprusside
Nitrovasodilators
Ocular
Organic Nitrates

Papilledema
PCWP
Peacock
Perioperative hypertension
Pheochromocytoma
Pollack
JNC 7
Pregnancy
Pregnancy-Induced HTN
Prehypertension
Primary aldosteronism
Psychomotor agitation
Rapid Onset of Effect
Reflex tachycardia
Renal
Renal dysfunction
Retinal hemorrhages
Secondary hypertension
Stage 1 hypertension
Stage 2 hypertension
Stage 3 hypertension
Systolic
Terry Ferguson
UFH
Vascular Dysfunction Syndromes
VELOCITY